Iron Supplements for Infants at Risk for Iron Deficiency

• Main Authors: Brianna C. MacQueen MD (Author), Vickie L. Baer RN (Author), Danielle M. Scott PharmD (Author), Con Yee Ling MD (Author), Elizabeth A. O'Brien MD (Author), Caitlin Boyer RD (Author), Erick Henry MPH (Author), Robert E. Fleming MD (Author), Robert D. Christensen MD (Author)
• Format: Book
• Published: SAGE Publishing, 2017-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Professional societies have published recommendations for iron dosing of preterm neonates, but differences exist between guidelines. To help develop standardized guidelines, we performed a 10-year analysis of iron dosing in groups at risk for iron deficiency: IDM (infants of diabetic mothers), SGA (small for gestational age), and VLBW premature neonates (very low birth weight, <1500 g). We analyzed iron dosing after red cell transfusions and erythropoiesis-stimulating agents (ESA). Of IDM, 11.8% received iron in the hospital; 9.8% of SGA and 27.1% of VLBW neonates received iron. Twenty percent of those who received iron had it started by day 14; 63% by 1 month. Supplemental iron was stopped after red cell transfusions in 73% of neonates receiving iron. An ESA was administered to 1677, of which 33% received iron within 3 days. This marked variation indicates that a consistent approach is needed, and using this report and a literature review, we standardized our iron-dosing guidelines.

Item Description

2333-794X
10.1177/2333794X17703836